Non-communicable diseases (NCDs), especially cardiovascular and liver disease, are among the leading causes of morbidity and mortality worldwide. Diabetes mellitus, hypertension, tobacco smoking, and dyslipidemia are the main aggravating risk factors and can negatively impact the incidence, severity, and clinical course of various types of cardiovascular and liver disease. These directly contribute to a complex set of pathological interactions. Dyslipidemia increases the risk of cardiovascular disease, the likelihood of dying from coronary events and is also closely related to the pathogenesis of metabolic-associated fatty liver disease. Lipid elevation results in an increase in liver enzymes and alterations in liver enzyme function, which may progress to steatohepatitis and cellular hepatocarcinoma. The relationship between metabolic-associated fatty liver disease and cardiovascular disorders can lead to a higher risk of undesirable outcomes in several patient groups. Metabolic-associated fatty liver disease is also considered an independent determinant of cardiovascular disease. In this way, this condition is a complex problem with implications far beyond the liver.
Among the therapeutic options available to treat liver and cardiovascular diseases, herbal medicines or other biologically active compounds stand out. Medicinal plants and their metabolites have been used for centuries and remain an important therapeutic resource around the world. Despite widespread use, many compounds have not experienced careful scientific investigation, whether they are studies of efficacy, toxicity, or drug-to-drug interactions. In addition, there are systematic efforts to discover new therapeutic options with natural and/or synthetic products for the treatment of cardiovascular diseases related to liver disorders.
In this Research Topic, we would like to invite investigators to submit preclinical or clinical studies focusing on the potential of biologically active products for the treatment of cardiovascular diseases related to liver disorders, especially those related to multiple risk factors. We will consider both original research and review articles.
Potential topics include but are not limited to the following:
• Animal models of cardiovascular or liver disease associated with multiple risk factors.
• Isolation and characterization of natural products with cardiovascular and hepatoprotective effects.
• Preclinical and clinical trials of plant-derived medicines and/or synthetic products for the treatment of cardiovascular and hepatic diseases.
• Efficacy and safety of natural and/or synthetic products for the treatment of cardiovascular or metabolic-associated fatty liver disease.
• Systematic reviews of natural products with cardiovascular and hepatoprotective effects focused on multiple targets (for submissions to Ethnopharmacology
and Gastrointestinal and Hepatic Pharmacology only).
• Synergistic effects of drugs and natural and/or synthetic products on cardiovascular and liver protection.
-------
All the manuscripts submitted to the collection will need to fully comply with the
Four Pillars of Best Practice in Ethnopharmacology (you can freely download the full version
here).
